PMID- 35174073 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220501 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 11 DP - 2021 TI - Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center. PG - 835889 LID - 10.3389/fonc.2021.835889 [doi] LID - 835889 AB - OBJECTIVE: This study was conducted in order to compare the efficacy and safety of transarterial chemoembolization (TACE) plus apatinib plus camrelizumab (TACE+AC) and apatinib plus camrelizumab (AC) in the treatment of unresectable hepatocellular carcinoma (HCC) in a real-world setting. METHODS: In this single-center retrospective study, the data of patients with unresectable HCC who had received TACE+AC or AC treatment during March 2017 to May 2021 were assessed. Patients in the AC group received intravenous administration of camrelizumab 200 mg every 3 weeks and oral apatinib 250 mg/day treatment. Patients in the TACE+AC group received the same dose of camrelizumab and apatinib 1 week after TACE. The primary endpoint of the study was overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) as the secondary endpoints. RESULTS: A total of 108 patients were enrolled in the study. There were 52 patients in the AC group and 56 patients in TACE+AC group. Median OS was significantly longer in the TACE+AC group than in the AC group (24.8 vs. 13.1 months; P = 0.005). Patients in the TACE+AC group achieved a higher ORR [24 (42.9%) vs. 9 (17.3%), P = 0.004] than those in the AC group. Patients in the TACE+AC group also achieved a higher disease control rate (DCR) [48 (85.7%) vs. 30 (57.7%), P = 0.001] than patients in the AC group. There was no significant difference in the incidence of AEs related to apatinib and camrelizumab between the two groups, except for gastrointestinal reaction (P > 0.05, all; P < 0.05, gastrointestinal reaction). CONCLUSION: TACE plus apatinib plus camrelizumab significantly improved OS, ORR, and DCR over apatinib plus camrelizumab in patients with unresectable HCC. AEs were tolerable and manageable. CI - Copyright (c) 2022 Ju, Zhou, Yang, Wang, Liu, Wang, Huang, Li, Chen, Bai, Yao and Xiong. FAU - Ju, Shuguang AU - Ju S AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China. FAU - Zhou, Chen AU - Zhou C AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China. FAU - Yang, Chongtu AU - Yang C AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China. FAU - Wang, Chaoyang AU - Wang C AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China. FAU - Liu, Jiacheng AU - Liu J AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China. FAU - Wang, Yingliang AU - Wang Y AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China. FAU - Huang, Songjiang AU - Huang S AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China. FAU - Li, Tongqiang AU - Li T AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China. FAU - Chen, Yang AU - Chen Y AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China. FAU - Bai, Yaowei AU - Bai Y AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China. FAU - Yao, Wei AU - Yao W AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China. FAU - Xiong, Bin AU - Xiong B AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China. LA - eng PT - Journal Article DEP - 20220131 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC8841670 OTO - NOTNLM OT - comprehensive therapy OT - hepatocellular carcinoma OT - immunotherapy OT - targeted therapy OT - transarterial chemoembolization COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/02/18 06:00 MHDA- 2022/02/18 06:01 PMCR- 2021/01/01 CRDT- 2022/02/17 05:37 PHST- 2021/12/15 00:00 [received] PHST- 2021/12/29 00:00 [accepted] PHST- 2022/02/17 05:37 [entrez] PHST- 2022/02/18 06:00 [pubmed] PHST- 2022/02/18 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2021.835889 [doi] PST - epublish SO - Front Oncol. 2022 Jan 31;11:835889. doi: 10.3389/fonc.2021.835889. eCollection 2021.